{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:34:23Z","timestamp":1785900863962,"version":"3.56.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40265-020-01460-3","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T11:14:51Z","timestamp":1609845291000},"page":"333-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-8014","authenticated-orcid":false,"given":"Jurij","family":"Hanzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0274","authenticated-orcid":false,"given":"Niels Vande","family":"Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-2033","authenticated-orcid":false,"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-0338","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-3822","authenticated-orcid":false,"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"issue":"8","key":"1460_CR1","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982\u201392.","journal-title":"Inflamm Bowel Dis."},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"5354320","DOI":"10.1155\/2019\/5354320","volume":"2019","author":"C Marinelli","year":"2019","unstructured":"Marinelli C, Savarino E, Inferrera M, Lorenzon G, Rigo A, Ghisa M, et al. Factors influencing disability and quality of life during treatment: a cross-sectional study on IBD patients. Gastroenterol Res Pract. 2019;2019:5354320.","journal-title":"Gastroenterol Res Pract."},{"issue":"5","key":"1460_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","volume":"13","author":"CRH Hedin","year":"2019","unstructured":"Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541\u201354.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"1460_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nri1784","volume":"6","author":"DH Adams","year":"2006","unstructured":"Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244\u201351.","journal-title":"Nat Rev Immunol."},{"issue":"8","key":"1460_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med."},{"issue":"8","key":"1460_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med."},{"issue":"4","key":"1460_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116\u201322.","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"1460_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ajg.2010.343","volume":"106","author":"SR Vavricka","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"1460_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","volume":"10","author":"K Karmiris","year":"2016","unstructured":"Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10(4):429\u201336.","journal-title":"J Crohns Colitis."},{"issue":"8","key":"1460_CR10","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794\u2013800.","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"1460_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"FT Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29\u201334.","journal-title":"J Clin Gastroenterol."},{"issue":"4","key":"1460_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ecco-jcc\/jjv238","volume":"10","author":"M Severs","year":"2016","unstructured":"Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):455\u201361.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"1460_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"AJ Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55(5):401\u201312.","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"1460_CR14","first-page":"711","volume":"85","author":"USJ Mons\u00e9n","year":"1990","unstructured":"Mons\u00e9n USJ, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: and epidemiological study. Am J Gastroenterol. 1990;85(6):711\u20136.","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"1460_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","volume":"10","author":"S Taleban","year":"2016","unstructured":"Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, et al. Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits. J Crohns Colitis. 2016;10(1):43\u20139.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"1460_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"TR Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387\u201391.","journal-title":"Gut"},{"issue":"12","key":"1460_CR17","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8","volume":"44","author":"S Smale","year":"2001","unstructured":"Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum. 2001;44(12):2728\u201336.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"1460_CR18","first-page":"631","volume":"11","author":"MC Karreman","year":"2017","unstructured":"Karreman MC, Luime JJ, Hazes JMW, Weel A. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11(5):631\u201342.","journal-title":"J Crohns Colitis."},{"issue":"2","key":"1460_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2036.2008.03868.x","volume":"29","author":"TR Orchard","year":"2009","unstructured":"Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP, et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn\u2019s disease. Aliment Pharmacol Ther. 2009;29(2):193\u20137.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"1460_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.crohns.2010.10.006","volume":"5","author":"M Polcz","year":"2011","unstructured":"Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services\u2019 Adult Hospital 1998\u20132009. J Crohns Colitis. 2011;5(2):148\u201351.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"1460_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/01.MIB.0000442011.60285.68","volume":"20","author":"A Weizman","year":"2014","unstructured":"Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20(3):525\u201333.","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"1460_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.survophthal.2003.08.004","volume":"48","author":"FD Ghanchi","year":"2003","unstructured":"Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv Ophthalmol. 2003;48(6):663\u201376.","journal-title":"Surv Ophthalmol."},{"issue":"10","key":"1460_CR23","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.14309\/ajg.0000000000000268","volume":"114","author":"RT Yokoda","year":"2019","unstructured":"Yokoda RT, Carey EJ. Primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114(10):1593\u2013605.","journal-title":"Am J Gastroenterol."},{"issue":"8","key":"1460_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1440-1746.2012.07150.x","volume":"27","author":"L Prideaux","year":"2012","unstructured":"Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27(8):1266\u201380.","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"1460_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MEG.0000000000000747","volume":"29","author":"M Fraga","year":"2017","unstructured":"Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, et al. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol. 2017;29(1):91\u20137.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"12","key":"1460_CR26","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/ibd.20529","volume":"14","author":"DH Bruining","year":"2008","unstructured":"Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV Jr. Prevalence of penetrating disease and extraintestinal manifestations of Crohn\u2019s disease detected with CT enterography. Inflamm Bowel Dis. 2008;14(12):1701\u20136.","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"1460_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0952-7915(00)00096-0","volume":"12","author":"JJ Campbell","year":"2000","unstructured":"Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000;12(3):336\u201341.","journal-title":"Curr Opin Immunol"},{"issue":"5258","key":"1460_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1126\/science.272.5258.60","volume":"272","author":"EC Butcher","year":"1996","unstructured":"Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272(5258):60\u20136.","journal-title":"Science"},{"issue":"9940","key":"1460_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","volume":"384","author":"S Vermeire","year":"2014","unstructured":"Vermeire S, O\u2019Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309\u201318.","journal-title":"Lancet"},{"issue":"1","key":"1460_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn\u2019s disease. N Engl J Med. 2003;348(1):24\u201332.","journal-title":"N Engl J Med."},{"issue":"5","key":"1460_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1586\/1744666X.2.5.759","volume":"2","author":"M Svensson","year":"2006","unstructured":"Svensson M, Agace WW. Role of CCL25\/CCR9 in immune homeostasis and disease. Expert Rev Clin Immunol. 2006;2(5):759\u201373.","journal-title":"Expert Rev Clin Immunol."},{"key":"1460_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaut.2016.01.001","volume":"68","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Bruns T, Ward S, Mai M, Schmidt C, Hirschfield GM, et al. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. J Autoimmun. 2016;68:98\u2013104.","journal-title":"J Autoimmun."},{"issue":"11","key":"1460_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1084\/jem.20041035","volume":"200","author":"B Eksteen","year":"2004","unstructured":"Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200(11):1511\u20137.","journal-title":"J Exp Med."},{"issue":"5","key":"1460_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","volume":"33","author":"AJ Grant","year":"2001","unstructured":"Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology. 2001;33(5):1065\u201372.","journal-title":"Hepatology"},{"issue":"9","key":"1460_CR35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","volume":"74","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739\u201347.","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"1460_CR36","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.4049\/jimmunol.166.7.4650","volume":"166","author":"M Salmi","year":"2001","unstructured":"Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166(7):4650\u20137.","journal-title":"J Immunol."},{"issue":"1","key":"1460_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1084\/jem.181.1.137","volume":"181","author":"M Salmi","year":"1995","unstructured":"Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med. 1995;181(1):137\u201349.","journal-title":"J Exp Med."},{"issue":"6","key":"1460_CR38","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","volume":"180","author":"JD Taurog","year":"1994","unstructured":"Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359\u201364.","journal-title":"J Exp Med."},{"issue":"8964","key":"1460_CR39","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/S0140-6736(95)91089-1","volume":"345","author":"RH Scofield","year":"1995","unstructured":"Scofield RH, Kurien B, Gross T, Warren WL, Harley JB, Scofield RH, et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. The Lancet. 1995;345(8964):1542\u20134.","journal-title":"The Lancet."},{"issue":"40","key":"1460_CR40","doi-asserted-by":"publisher","first-page":"37573","DOI":"10.1074\/jbc.M205470200","volume":"277","author":"M Ramos","year":"2002","unstructured":"Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, de Castro LJA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem. 2002;277(40):37573\u201381.","journal-title":"J Biol Chem."},{"issue":"2","key":"1460_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.07.014","volume":"43","author":"R Horai","year":"2015","unstructured":"Horai R, Z\u00e1rate-Blad\u00e9s Carlos R, Dillenburg-Pilla P, Chen J, Kielczewski Jennifer L, Silver Phyllis B, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity. 2015;43(2):343\u201353.","journal-title":"Immunity"},{"issue":"1","key":"1460_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0016-5085(95)90263-5","volume":"109","author":"L Biancone","year":"1995","unstructured":"Biancone L, Mandal A, Yang H, Dasgupta T, Paoluzi AO, Marcheggiano A, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109(1):3\u201312.","journal-title":"Gastroenterology"},{"issue":"5","key":"1460_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0016-5085(98)70310-5","volume":"114","author":"X Geng","year":"1998","unstructured":"Geng X, Biancone L, Dai HH, Lin JJC, Yoshizaki N, Dasgupta A, et al. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114(5):912\u201322.","journal-title":"Gastroenterology"},{"issue":"2","key":"1460_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/0016-5085(90)90839-S","volume":"98","author":"KM Das","year":"1990","unstructured":"Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology. 1990;98(2):464\u20139.","journal-title":"Gastroenterology"},{"issue":"1","key":"1460_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0016-5085(94)90066-3","volume":"107","author":"S Bhagat","year":"1994","unstructured":"Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994;107(1):103\u20138.","journal-title":"Gastroenterology"},{"issue":"9","key":"1460_CR46","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1084\/jem.20091233","volume":"206","author":"AM Smith","year":"2009","unstructured":"Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn\u2019s disease. J Exp Med. 2009;206(9):1883\u201397.","journal-title":"J Exp Med."},{"issue":"4","key":"1460_CR47","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","volume":"16","author":"JH Park","year":"2017","unstructured":"Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16(4):416\u201326.","journal-title":"Autoimmun Rev."},{"issue":"6","key":"1460_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s100670070003","volume":"19","author":"R Queiro","year":"2000","unstructured":"Queiro R, Maiz O, Intxausti J, de Dios JR, Belzunegui J, Gonzalez C, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol. 2000;19(6):445\u20139.","journal-title":"Clin Rheumatol."},{"issue":"1","key":"1460_CR49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1440-1746.2007.05108.x","volume":"23","author":"H Peeters","year":"2008","unstructured":"Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, et al. Clinical and genetic factors associated with sacroiliitis in Crohn\u2019s disease. J Gastroenterol Hepatol. 2008;23(1):132\u20137.","journal-title":"J Gastroenterol Hepatol."},{"issue":"6","key":"1460_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1155\/2001\/612531","volume":"15","author":"G Fornaciari","year":"2001","unstructured":"Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol. 2001;15(6):399\u2013403.","journal-title":"Can J Gastroenterol."},{"issue":"10","key":"1460_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009;68(10):1520\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"1460_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239\u201354.","journal-title":"J Crohns Colitis."},{"issue":"6","key":"1460_CR53","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649\u201370.","journal-title":"J Crohns Colitis."},{"key":"1460_CR54","first-page":"1104","volume":"22","author":"M Creemers","year":"1995","unstructured":"Creemers M, Franssen M, van de Putte L, Gribnau F, van Riel P. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol. 1995;22:1104\u20137.","journal-title":"J Rheumatol."},{"issue":"3","key":"1460_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00124743-199806000-00007","volume":"4","author":"B Ostendorf","year":"1998","unstructured":"Ostendorf B, Specker C, Schneider M. Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis. J Clin Rheumatol. 1998;4(3):129\u201336.","journal-title":"J Clin Rheumatol."},{"issue":"1","key":"1460_CR56","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/ard.2003.019174","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005;64(1):124\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"1460_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","volume":"101","author":"Y El Miedany","year":"2006","unstructured":"El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311\u20137.","journal-title":"Am J Gastroenterol."},{"key":"1460_CR58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","volume":"4","author":"WJ Sandborn","year":"2006","unstructured":"Sandborn WJ, Stenson WJ, Brynskov J, Lorenz RG, Steidle G, Robbins J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled pilot study. Clin Gastroenterol Hepatol. 2006;4:203\u201311.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1460_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrgastro.2015.208","volume":"13","author":"P Gionchetti","year":"2016","unstructured":"Gionchetti P, Rizzello F. IBD: IBD and spondyloarthritis: joint management. Nat Rev Gastroenterol Hepatol. 2016;13(1):9\u201310.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"6","key":"1460_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"1460_CR61","first-page":"CD004800","volume":"27","author":"J Chen","year":"2014","unstructured":"Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014;27(11):CD004800.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"1460_CR62","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.1780380507","volume":"38","author":"M Dougados","year":"1995","unstructured":"Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995;38(5):618\u201327.","journal-title":"Arthritis Rheum."},{"issue":"12","key":"1460_CR63","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/art.1780391209","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2004\u201312.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"1460_CR64","first-page":"CD005468","volume":"18","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;18(4):CD005468.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"1460_CR65","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","volume":"97","author":"H Herfarth","year":"2002","unstructured":"Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn\u2019s disease. Am J Gastroenterol. 2002;97(10):2688\u201390.","journal-title":"Am J Gastroenterol."},{"issue":"9244","key":"1460_CR66","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","volume":"356","author":"F Van den Bosch","year":"2000","unstructured":"Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn\u2019s disease associated with spondyloarthropathy: effect of TNF- alpha blockade with infliximab on articular symptoms. Lancet. 2000;356(9244):1821\u20132.","journal-title":"Lancet"},{"issue":"12","key":"1460_CR67","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/ard.2003.012450","volume":"63","author":"S Generini","year":"2004","unstructured":"Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63(12):1664\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1460_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.21663","volume":"18","author":"R Lofberg","year":"2012","unstructured":"Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis. 2012;18:1\u20139.","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"1460_CR69","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03009740510026698","volume":"34","author":"A Rispo","year":"2005","unstructured":"Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn\u2019s disease. Scand J Rheumatol. 2005;34(5):387\u201391.","journal-title":"Scand J Rheumatol."},{"issue":"9","key":"1460_CR70","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","volume":"104","author":"M Barreiro-de-Acosta","year":"2012","unstructured":"Barreiro-de-Acosta M, Lorenzo A, Dominguez-Munoz JE. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn\u2019s disease. Rev Esp Enferm Dig. 2012;104(9):468\u201372.","journal-title":"Rev Esp Enferm Dig."},{"issue":"6","key":"1460_CR71","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"9894","key":"1460_CR72","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. The Lancet. 2013;382(9894):780\u20139.","journal-title":"The Lancet."},{"issue":"2","key":"1460_CR73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370.","journal-title":"Arthritis Rheumatol."},{"key":"1460_CR74","first-page":"69","volume":"12","author":"S Matsumoto","year":"2018","unstructured":"Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn\u2019s disease. Biologics. 2018;12:69\u201373.","journal-title":"Biologics."},{"issue":"11","key":"1460_CR75","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/14712598.2020.1830057","volume":"20","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, et al. Effectiveness of ustekinumab on Crohn\u2019s disease associated spondyloarthropathy: real-world data from the sicilian network for inflammatory bowel diseases (SN-IBD). Expert Opin Biol Ther. 2020;20(11):1381\u20134.","journal-title":"Expert Opin Biol Ther."},{"issue":"8","key":"1460_CR76","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"1460_CR77","doi-asserted-by":"publisher","first-page":"e00226","DOI":"10.14309\/crj.0000000000000226","volume":"6","author":"W Wang","year":"2019","unstructured":"Wang W, Cleveland NK, Ollech J, Rubin DT. Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis. ACG Case Rep J. 2019;6(9):e00226.","journal-title":"ACG Case Rep J."},{"issue":"4","key":"1460_CR78","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","volume":"17","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Loeuille D, Peyrin-Biroulet L. Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy. Clin Gastroenterol Hepatol. 2019;17(4):794\u20136.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"1460_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.MIB.0000436959.62286.f9","volume":"20","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20(1):213\u201327.","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"1460_CR80","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/ibd\/izy174","volume":"24","author":"I Plumptre","year":"2018","unstructured":"Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: a review for the gastroenterologist. Inflamm Bowel Dis. 2018;24(12):2510\u20137.","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"1460_CR81","first-page":"615","volume":"80","author":"SHTJ Mir-Madjlessi","year":"1985","unstructured":"Mir-Madjlessi SHTJ, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80(8):615\u201320.","journal-title":"Am J Gastroenterol."},{"issue":"18","key":"1460_CR82","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa013383","volume":"347","author":"RH Weenig","year":"2002","unstructured":"Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347(18):1412\u20138.","journal-title":"N Engl J Med."},{"issue":"2","key":"1460_CR83","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12016-012-8351-x","volume":"45","author":"AV Marzano","year":"2013","unstructured":"Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet\u2019s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45(2):202\u201310.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"3","key":"1460_CR84","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5858\/arpa.2010-0666-RS","volume":"136","author":"A Siroy","year":"2012","unstructured":"Siroy A, Wasman J. Metastatic Crohn disease: a rare cutaneous entity. Arch Pathol Lab Med. 2012;136(3):329\u201332.","journal-title":"Arch Pathol Lab Med."},{"issue":"3","key":"1460_CR85","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","volume":"26","author":"S Timani","year":"2008","unstructured":"Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26(3):265\u201373.","journal-title":"Clin Dermatol."},{"issue":"6","key":"1460_CR86","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1365-2230.2006.02221.x","volume":"31","author":"TH Clayton","year":"2006","unstructured":"Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31(6):823\u20134.","journal-title":"Clin Exp Dermatol."},{"issue":"5","key":"1460_CR87","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaad.2016.06.016","volume":"75","author":"KS Thomas","year":"2016","unstructured":"Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol. 2016;75(5):940\u20139.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"1460_CR88","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/archdermatol.2010.393","volume":"147","author":"L Le Cleach","year":"2011","unstructured":"Le Cleach L, Moguelet P, Perrin P, Chosidow O. Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol. 2011;147(1):101\u20133.","journal-title":"Arch Dermatol."},{"issue":"350","key":"1460_CR89","doi-asserted-by":"publisher","first-page":"h2958","DOI":"10.1136\/bmj.h2958","volume":"12","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;12(350):h2958.","journal-title":"BMJ"},{"issue":"4","key":"1460_CR90","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505\u20139.","journal-title":"Gut"},{"issue":"10","key":"1460_CR91","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","volume":"58","author":"F Arg\u00fcelles-Arias","year":"2013","unstructured":"Arg\u00fcelles-Arias F, Castro-Laria L, Lobat\u00f3n T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949\u201354.","journal-title":"Dig Dis Sci"},{"key":"1460_CR92","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/apt.15766","volume":"51","author":"J Wang","year":"2020","unstructured":"Wang J, Prenner J, Wang W, Sakuraba A, Hyman N, Dalal S, et al. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:1365\u201372.","journal-title":"Aliment Pharmacol Ther."},{"key":"1460_CR93","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/ecco-jcc\/jjaa078","volume":"14","author":"FM Phillips","year":"2020","unstructured":"Phillips FM, Verstockt B, Sebastian S, Ribaldone DG, Vavricka S, Katsanos K, et al. Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. J Crohns Colitis. 2020;14:1488\u201393.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"1460_CR94","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991\u20133.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"32","key":"1460_CR95","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","volume":"23","author":"LL Troncoso","year":"2017","unstructured":"Troncoso LL, Biancardi AL, de Moraes HV, Zaltman CJR. Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World J Gastroenterol. 2017;23(32):5836\u201348.","journal-title":"World J Gastroenterol."},{"issue":"12","key":"1460_CR96","first-page":"1110","volume":"16","author":"HHRA Leibowitz","year":"1984","unstructured":"Leibowitz HHRA, Lindsey C, Rosenthal AL. Fluorometholone acetate: clinical evaluation in the treatment of external ocular inflammation. Ann Ophthalmol. 1984;16(12):1110\u20135.","journal-title":"Ann Ophthalmol."},{"issue":"6","key":"1460_CR97","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387\u201395.","journal-title":"Hepatology"},{"issue":"3","key":"1460_CR98","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-96 e3.","journal-title":"Ophthalmology"},{"issue":"10","key":"1460_CR99","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. The New England journal of medicine. 2016;375(10):932\u201343.","journal-title":"The New England journal of medicine."},{"key":"1460_CR100","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","volume":"14","author":"T Chateau","year":"2020","unstructured":"Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn\u2019s disease. J Crohns Colitis. 2020;14:571.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"1460_CR101","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","volume":"42","author":"DW Hommes","year":"2008","unstructured":"Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522\u20136.","journal-title":"J Clin Gastroenterol."},{"issue":"2","key":"1460_CR102","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/apt.14829","volume":"48","author":"CS Tse","year":"2018","unstructured":"Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(2):190\u20135.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"1460_CR103","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","volume":"18","author":"CRH Hedin","year":"2020","unstructured":"Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, et al. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2020;18(10):2295-304e2.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"1460_CR104","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1055\/s-0043-107029","volume":"49","author":"L Aabakken","year":"2017","unstructured":"Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy. 2017;49(6):588\u2013608.","journal-title":"Endoscopy."},{"issue":"1","key":"1460_CR105","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","volume":"13","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Sandborn WJ, Colombel JF, O\u2019Byrne S, Khalid JM, Kempf C, et al. Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13(1):50\u20137.","journal-title":"J Crohns Colitis."},{"issue":"7","key":"1460_CR106","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.dld.2018.02.013","volume":"50","author":"FS Macaluso","year":"2018","unstructured":"Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018;50(7):675\u201381.","journal-title":"Dig Liver Dis."},{"issue":"9","key":"1460_CR107","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izy065","volume":"24","author":"MC Dubinsky","year":"2018","unstructured":"Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(9):1876\u201382.","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"1460_CR108","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1093\/ibd\/izy127","volume":"24","author":"T Cai","year":"2018","unstructured":"Cai T, Lin TC, Bond A, Huang J, Kane-Wanger G, Cagan A, et al. The association between arthralgia and vedolizumab using natural language processing. Inflamm Bowel Dis. 2018;24(10):2242\u20136.","journal-title":"Inflamm Bowel Dis."},{"key":"1460_CR109","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","volume":"59","author":"A Dupr\u00e9","year":"2020","unstructured":"Dupr\u00e9 A, Collins M, Nocturne G, Carbonnel F, Mariette X, Seror R. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Rheumatology (Oxford). 2020;59:3275\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1460_CR110","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/apt.14419","volume":"47","author":"S Tadbiri","year":"2018","unstructured":"Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47(4):485\u201393.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"1460_CR111","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-018-4357-y","volume":"38","author":"S Tamanini","year":"2019","unstructured":"Tamanini S, Fredi M, Crisafulli F, Lazzaroni MG, Tincani A, Franceschini F. Letter to editor: new onset\/recurrence of inflammatory arthralgia\/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clin Rheumatol. 2019;38(2):609\u201310.","journal-title":"Clin Rheumatol."},{"issue":"6","key":"1460_CR112","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/rheumatology\/key267","volume":"58","author":"S Dubash","year":"2019","unstructured":"Dubash S, Marianayagam T, Tinazzi I, Al-Araimi T, Pagnoux C, Weizman AV, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019;58(6):963\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1460_CR113","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","volume":"76","author":"G Varkas","year":"2017","unstructured":"Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-Gurdian F, Cypers H, et al. An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76(5):878\u201381.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1460_CR114","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","volume":"63","author":"M Fleisher","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018;63(4):825\u201333.","journal-title":"Dig Dis Sci."},{"issue":"2","key":"1460_CR115","first-page":"75","volume":"16","author":"LI Diaz","year":"2020","unstructured":"Diaz LI, Keihanian T, Schwartz I, Kim SB, Calmet F, Quintero MA, et al. Vedolizumab-induced de novo extraintestinal manifestations. Gastroenterol Hepatol. 2020;16(2):75\u201381.","journal-title":"Gastroenterol Hepatol."},{"issue":"10","key":"1460_CR116","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","volume":"13","author":"B Caron","year":"2019","unstructured":"Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID Multicentre Cohort Study. J Crohn\u2019s Colitis. 2019;13(10):1239\u201347.","journal-title":"J Crohn's Colitis."},{"issue":"6","key":"1460_CR117","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/apt.14525","volume":"47","author":"B Christensen","year":"2018","unstructured":"Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47(6):753\u201362.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"1460_CR118","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","volume":"18","author":"KD Lynch","year":"2020","unstructured":"Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(1):179-87e6.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"1460_CR119","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","volume":"43","author":"PP Stanich","year":"2011","unstructured":"Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43(4):309\u201313.","journal-title":"Dig Liver Dis."},{"issue":"3","key":"1460_CR120","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808\u201314.","journal-title":"Hepatology"},{"issue":"6","key":"1460_CR121","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/rheumatology\/kez056","volume":"58","author":"S Alivernini","year":"2019","unstructured":"Alivernini S, Pugliese D, Tolusso B, Felice C, Gremese E, Armuzzi A. Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019;58(6):1113\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1460_CR122","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","volume":"13","author":"G Fiorino","year":"2014","unstructured":"Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15\u20139.","journal-title":"Autoimmun Rev."},{"issue":"5","key":"1460_CR123","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"3","key":"1460_CR124","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2019.05.006","volume":"71","author":"M de Krijger","year":"2019","unstructured":"de Krijger M, Wildenberg ME, de Jonge WJ, Ponsioen CY. Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol. 2019;71(3):603\u201315.","journal-title":"J Hepatol."},{"issue":"3","key":"1460_CR125","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ecco-jcc\/jjx158","volume":"12","author":"SR Vavricka","year":"2018","unstructured":"Vavricka SR, Galvan JA, Dawson H, Soltermann A, Biedermann L, Scharl M, et al. Expression patterns of TNFalpha, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohns Colitis. 2018;12(3):347\u201354.","journal-title":"J Crohns Colitis."},{"issue":"1","key":"1460_CR126","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ajg.2017.395","volume":"113","author":"D Lissner","year":"2018","unstructured":"Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, et al. Pulmonary manifestation of Crohn\u2019s disease developed under treatment with vedolizumab. Am J Gastroenterol. 2018;113(1):146\u20138.","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"1460_CR127","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"1460_CR128","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1460_CR129","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.28256","volume":"63","author":"CY Ponsioen","year":"2016","unstructured":"Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology. 2016;63(4):1357\u201367.","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01596-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01460-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01460-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01460-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:37:07Z","timestamp":1697495827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01460-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01460-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-021-01596-w","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"5 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01596-w","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01596-w","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JH has received speaker\u2019s fees from Biogen, Janssen, and Takeda. CM has received consulting fees from AbbVie, AVIR Pharma Inc, Janssen, Takeda, Pfizer, Roche, and Alimentiv (formerly Robarts Clinical Trials Inc.); speaker's fees from AbbVie, Janssen, Takeda, and Pfizer; and research support from the Canadian IBD Research Consortium and Pfizer. NVC has received research grants from R-Biopharm; grants and personal fees from Takeda and UCB; and personal fees from Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.), Celltrion, and Prometheus. These activities were all outside of the submitted work. RK has received consulting fees from AbbVie, Janssen, Takeda, Roche, Pendopharm, Lilly, Encycle, Shire, Alimentiv (formerly Robarts Clinical Trials Inc.), Pfizer, Inomar, and Merck. VJ has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Alimentiv (formerly Robarts Clinical Trials Inc.), Topivert, and Celltrion and speaker\u2019s fees from Takeda, Janssen, Shire, Ferring, AbbVie, and Pfizer. BGF has received grant\/research support from AbbVie Inc., Amgen Inc., AstraZeneca\/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer Ingelheim, Celgene Corporation, Celltech, Genentech Inc\/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc.\/Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, and UCB; consulting fees from Abbott\/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, AstraZeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer Ingelheim, Bristol Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring Pharma, Roche\/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, JnJ\/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., and Zyngenia; speakers bureau fees from Abbott\/AbbVie, JnJ\/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; is a scientific advisory board member for Abbott\/AbbVie, Allergan, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor Inc., Elan\/Biogen, Galapagos, Genentech\/Roche, JnJ\/Janssen, Merck, Nestle, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is the Senior Scientific Officer of Alimentiv Inc. (formerly Robarts Clinical Trials Inc.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material:"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All authors contributed to the drafting of the work or revising it critically for important intellectual content.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}